U.S. Markets closed

Harvard Bioscience, Inc. (HBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.53+0.25 (+3.98%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.28
Open6.58
Bid6.52 x 1800
Ask6.63 x 900
Day's Range6.42 - 6.58
52 Week Range2.06 - 7.14
Volume171,509
Avg. Volume214,275
Market Cap260.061M
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-0.20
Earnings DateMay 03, 2021 - May 07, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.75
  • We Might See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO) Soon
    Simply Wall St.

    We Might See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO) Soon

    With the business potentially at an important milestone, we thought we'd take a closer look at Harvard Bioscience...

  • Benzinga

    Harvard Bioscience: Q4 Earnings Insights

    Shares of Harvard Bioscience (NASDAQ:HBIO) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 0.00% year over year to $0.08, which beat the estimate of $0.06. Revenue of $30,984,000 rose by 0.04% from the same period last year, which beat the estimate of $27,130,000. Outlook Earnings guidance hasn't been issued by the company for now. Revenue guidance hasn't been issued by the company for now. How To Listen To The Conference Call Date: Mar 10, 2021 View more earnings on HBIO Time: 08:00 AM ET Webcast URL: https://edge.media-server.com/mmc/p/s8sggrzy Recent Stock Performance 52-week high: $5.21 Company's 52-week low was at $1.39 Price action over last quarter: Up 23.98% Company Profile Harvard Bioscience Inc is a US-based developer, manufacturer and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America and Europe, it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS. The majority of its revenue comes from the United States. See also: Best Cryptocurrency Apps See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 10, 2021Preview: Harvard Bioscience's Earnings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Harvard Bioscience Announces Fourth Quarter 2020 Financial Results
    GlobeNewswire

    Harvard Bioscience Announces Fourth Quarter 2020 Financial Results

    Sales effectiveness focus with disciplined cost management results in improved revenues and margins while reducing debtRevenue returns to pre-Covid19 levels on strong CRO/pharma salesOperating margin increased year-over-year on GAAP and an adjusted basisNew debt facility significantly reduces annual interest expense HOLLISTON, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the three months and year ended December 31, 2020. Jim Green, Chairman and CEO said, “Our fourth quarter demonstrated the benefits of our sales effectiveness focus as we delivered revenue at pre-Covid levels, or $31.0 million. Our preclinical product revenue increased 19% over Q4 2019. In addition, we are very pleased to have successfully refinanced our credit facility which is expected to save approximately $3M annually in cash interest based upon current debt levels and provides numerous other enhancements compared to the former facility.” Green concluded, “With strong CRO/Pharma growth and recovering academic lab sales, we expect revenue to grow 8 to 12% compared to 2020. In addition, exciting new products along with removal of lower value offerings is expected to improve our profit mix, delivering adjusted operating margins in the mid-to-upper teens in 2021. We believe the strong 2020 ending and our focus on growth and new exciting products puts 2021 on plan to creating the growth oriented profitable platform we envisioned.” Quarterly Financial Results Summary Q4'20 Q3'20 Q4'19 Revenue $31.0 million $24.0 million $31.0 million Operating Income (GAAP) $2.8 million $0.2 million $1.6 million Adjusted Operating Income $5.8 million $3.6 million $5.6 million Operating Margin (GAAP) 8.9% 0.8% 5.3% Adjusted Operating Margin 18.7% 14.8% 18.1% Diluted (Loss) Earnings Per Share (GAAP) ($0.02) ($0.03) $0.01 Adjusted Diluted Earnings Per Share $0.08 $0.04 $0.08 Net Debt* $41.1 million $41.6 million $46.7 million * Debt outstanding less cash and cash equivalents Please refer to the exhibits below for a reconciliation of certain non-GAAP to GAAP financial measures, including operating income, net income and loss, and diluted earnings per share. Please see “Use of Non-GAAP Financial Information” for additional information regarding our use of such adjusted financial information. Webcast and Conference Call Details Harvard Bioscience will be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID# 4375572. The conference call will be simultaneously webcast and can be accessed through the Harvard Bioscience website. A slide presentation that will be referenced during the webcast will be posted to our Investor Relations website shortly before the webcast begins. To listen to the webcast, log on to the webcast at: http://investor.harvardbioscience.com/ and click on the Earnings Call icon. Use of Non-GAAP Financial Information In this press release, we have included non-GAAP financial information including adjusted operating income, adjusted net income, and adjusted diluted earnings per share. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income primarily resulting from purchase accounting or events that we do not believe are related to the underlying operations of the business such as amortization of intangibles related to acquisitions, costs related to acquisition, disposition and integration initiatives, impairment charges, severance, restructuring and other business transformation expenses, and stock-based compensation expense. They also exclude the tax impact of the reconciling items. This non-GAAP financial information approximates information used by our management to internally evaluate the operating results of the Company. Tabular reconciliations of our adjusted operating income, adjusted net income (loss), and adjusted earnings (loss) per diluted share are included as exhibits below in this press release. The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information. About Harvard Bioscience Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Our customers range from renowned academic institutions and government laboratories, to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world. For more information, please visit our website at www.harvardbioscience.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. You can identify these statements by our use of such words as "will," "guidance," "objectives," "optimistic," "potential," "future," "expects," "plans," "estimates," "continue," "drive," "strategy," "potential," "potentially," "growth," "long-term," "projects," "projected," "intends," "believes," "goals," "sees," "seek," "develop" "possible" "new," "emerging," "opportunity," "pursue" and similar expressions that do not relate to historical matters. Forward-looking statements in this press release or that may be made during our conference call may include, but are not limited to, statements or inferences about the Company's or management's beliefs or expectations, the Company's anticipated future revenues and earnings, the strength of the Company's market position and business model, industry outlook, the impact of the COVID-19 pandemic on the Company’s business, the Company's business strategy, the positioning of the Company for growth, the market demand and opportunity for the Company's current products, or products it is developing or intends to develop, and the Company's plans, objectives and intentions that are not historical facts. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Investors should note that many factors, as more fully described under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, and in our Quarterly Reports on Form 10-Q issued in 2020 and in our other filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein may cause the Company's actual results to differ materially from those in the forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information. For investor inquiries, please contact Michael A. Rossi, Chief Financial Officer at (508) 893-8999. Exhibit 1 HARVARD BIOSCIENCE, INC. Consolidated Statements of Operations (unaudited, in thousands, except per share data) Three Months Ended December 31, 2020 September 30, 2020 December 31, 2019 Revenues$30,984 $24,037 $30,972 Cost of revenues 13,276 10,542 13,738 Gross profit 17,708 13,495 17,234 Operating expenses: Sales and marketing expenses 5,470 4,588 5,894 General and administrative expenses 5,681 5,399 5,545 Research and development expenses 2,349 1,949 2,645 Amortization of intangible assets 1,452 1,377 1,457 Impairment charges - - 59 Total operating expenses 14,952 13,313 15,600 Operating income 2,756 182 1,634 Other expense: Interest expense (1,094) (1,205) (1,281) Debt extinguishment and related costs (1,876) - - Other expense, net (334) (392) (255) Total other expense (3,304) (1,597) (1,536) (Loss) income before income taxes (548) (1,415) 98 Income tax expense (benefit) 67 (317) (452) Net (loss) income$(615) $(1,098) $550 (Loss) earnings per common share: Basic$(0.02) $(0.03) $0.01 Diluted$(0.02) $(0.03) $0.01 Weighted average common shares: Basic 39,021 38,920 38,068 Diluted 39,021 38,920 39,070 Exhibit 1.1 HARVARD BIOSCIENCE, INC. Consolidated Statements of Operations (unaudited, in thousands, except per share data) Year Ended December 31, 2020 2019 Revenues$102,100 $116,176 Cost of revenues 44,059 51,854 Gross profit 58,041 64,322 Operating expenses: Sales and marketing expenses 19,916 23,264 General and administrative expenses 23,509 22,760 Research and development expenses 8,685 10,715 Amortization of intangible assets 5,710 5,746 Impairment charges - 1,460 Total operating expenses 57,820 63,945 Operating income 221 377 Other expense: Interest expense (4,831) (5,410) Debt extinguishment and related costs (1,876) - Other expense, net (806) (469) Total other expense (7,513) (5,879) Loss before income taxes (7,292) (5,502) Income tax expense (benefit) 518 (815) Net loss$(7,810) $(4,687) Loss per common share: Basic and diluted$(0.20) $(0.12) Weighted average common shares: Basic and diluted 38,640 37,814 Exhibit 2 HARVARD BIOSCIENCE, INC. Condensed Consolidated Balance Sheets (unaudited, in thousands) December 31, 2020 December 31, 2019 Assets Cash and cash equivalents$8,317 $8,335 Accounts receivables 17,766 20,704 Inventories 22,262 22,061 Other current assets 3,355 2,472 Total current assets 51,700 53,572 Property, plant and equipment 3,960 4,776 Goodwill and other intangibles 91,741 95,786 Other long-term assets 8,853 10,736 Total assets$156,254 $164,870 Liabilities and Stockholders' Equity Current portion, long-term debt$1,721 $6,900 Other current liabilities 19,332 18,412 Total current liabilities 21,053 25,312 Long-term debt 46,286 46,917 Other long-term liabilities 12,234 10,947 Stockholders’ equity 76,681 81,694 Total liabilities and stockholders’ equity$156,254 $164,870 Exhibit 3 HARVARD BIOSCIENCE, INC. Condensed Consolidated Statements of Cash Flows (unaudited, in thousands) Year Ended December 31, 2020 2019 Cash flows from operating activities: Net loss$(7,810) $(4,687) Adjustments to operating cash flows 13,035 12,690 Changes in operating assets and liabilities 4,106 42 Net cash provided by operating activities 9,331 8,045 Cash flows from investing activities: Additions to property, plant and equipment (1,152) (1,216) Disposition of business - 1,002 Other investing activities (250) (15) Net cash used in investing activities (1,402) (229) Cash flows from financing activities: Proceeds from borrowings 61,315 4,300 Repayments of debt (66,912) (11,703) Payments of debt extinguishment and issuance costs (1,897) - Other financing activities (473) (221) Net cash used in financing activities (7,967) (7,624) Effect of exchange rate changes on cash 20 (30) (Decrease) increase in cash and cash equivalents (18) 162 Cash and cash equivalents at the beginning of year 8,335 8,173 Cash and cash equivalents at the end of year$8,317 $8,335 Exhibit 4 HARVARD BIOSCIENCE, INC. Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) (in thousands, except per share data) Three Months Ended December 31, September 30, December 31, 2020 2020 2019 GAAP operating income$2,756 $182 $1,634 Stock-based compensation expense 1,006 1,079 841 Severance, restructuring and transformation costs 532 876 1,551 Acquired assets amortization and impairments 1,503 1,428 1,575 Adjusted operating income$5,797 $3,565 $5,601 GAAP operating margin 8.9% 0.8% 5.3% Adjusted operating margin 18.7% 14.8% 18.1% GAAP net (loss) income$(615) $(1,098) $550 Stock-based compensation expense 1,006 1,079 841 Severance, restructuring and transformation costs 532 876 1,551 Debt extinguishment and related costs 1,876 - - Acquired assets amortization and impairments 1,503 1,428 1,575 Income taxes (A) (1,034) (823) (1,472) Adjusted net income$3,268 $1,462 $3,045 GAAP (loss) earnings per diluted share$(0.02) $(0.03) $0.01 Adjusted items after tax per share assuming dilution 0.10 0.07 0.07 Adjusted earnings per diluted share$0.08 $0.04 $0.08 Weighted average diluted common shares: GAAP 39,021 38,920 38,068 Adjusted 40,810 40,307 39,070 (A) Income taxes includes the tax effect of the adjustments to GAAP results. Exhibit 4.1 HARVARD BIOSCIENCE, INC. Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) (in thousands, except per share data) Year Ended December 31, 2020 2019 GAAP operating (loss) income$221 $377 Stock-based compensation expense 3,647 3,030 Severance, restructuring and transformation costs 4,166 3,943 Acquired assets amortization and impairments 5,920 7,503 Adjusted operating income$13,954 $14,853 GAAP operating margin 0.2% 0.3% Adjusted operating margin 13.7% 12.8% GAAP net loss$(7,810) $(4,687) Stock-based compensation expense 3,647 3,030 Severance, restructuring and transformation costs 4,166 3,943 Debt extinguishment and related costs 1,876 - Acquired assets amortization and impairments 5,920 7,503 Income taxes (A) (1,469) (2,766) Adjusted net income$6,330 $7,023 GAAP loss per diluted share $(0.20) $(0.12) Adjusted items after tax per share assuming dilution 0.36 0.30 Adjusted earnings per diluted share$0.16 $0.18 Weighted average diluted common shares: GAAP 38,640 37,814 Adjusted 39,985 38,373 (A) Income taxes includes the tax effect of the adjustments to GAAP results.